FGFR Alterations Emerge as Enticing Target in Multiple Tumor Types

Gina Battaglia, PhD
Published: Friday, Mar 29, 2019
Aberrations in fibroblast growth factor receptor (FGFR) signaling are an emerging focus for targeted therapy across multiple types of cancer, particularly urothelial carcinoma, gastric cancer, and intrahepatic cholangiocarcinoma. However, recent research findings demonstrating variability in the efficacy of FGFR-targeted therapies across different FGFR aberrations emphasize the importance of patient selection for clinical trials and further studies of combination regimens to be used with FGFR inhibitors.

Figure 1. FGFR Pathway Activity Implicated in Oncogenic Signaling7

Figure 1. FGFR Pathways Activity Implicated in Oncogenic Signaling7 Aberrations in FGFR represent a key target for cancer therapy for a subgroup of certain types of malignancies. A study using next-generation sequencing (NGS) on samples from about 5000 patients with various cancers showed FGFR aberrations in 7.1% (Figure 2). Amplifications in FGFR accounted for the majority of these aberrations (66%), followed by activating mutations (26%) and gene rearrangements or fusions (8%).8 Overall, aberrations in FGFR1/2/3/4 were most frequently found in urothelial (31.7%), breast (17.4%), endometrial (11.3%), and ovarian cancers (8.6%).8
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication